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Potassium Balances in Maintenance Hemodialysis
Hoon Young Choi, M.D.,
Sung Kyu Ha, M.D.
Potassium is abundant in the ICF compartment in the body and its excretion 
primarily depends on renal (about 90%), and to a lesser extent (about 10%) on 
colonic excretion. Total body potassium approximated to 50 mmol/kg body weight 
and 2% of total body potassium is in the ECF compartment and 98% of it in the 
intracellular compartment.Dyskalemia is a frequent electrolyte imbalance observed 
among the maintenance hemodialysis patients. In case of hyperkalemia, it is 
frequently “a silent and a potential life threatening electrolyte imbalance” among 
patients with ESRD under maintenance hemodialysis. The prevalence of hyper- 
kalemia in maintenance HD patients was reported to be about 8.7-10%. Mortality 
related to the hyperkalemia has been shown to be about 3.1/1,000 patient-years 
and about 24% of patients with HD required emergency hemodialysis due to 
severe hyperkalemia. In contrast to the hyperkalemia, much less attention has been 
paid to the hypokalemia in hemodialysis patients because of the low prevalence 
under maintenance hemodialysis patients. Severe hypokalemia in the hemodialysis 
patients usually was resulted from low potassium intake (malnutrition), chronic 
diarrhea, mineralocorticoid use, and imprudent use of K-exchange resins. Recently, 
the numbers of the new patients with advanced chronic kidney disease undergoing 
maintenance hemodialysis are tremendously increasing worldwide. However, 
the life expectancy of these patients is still much lower than that of the general 
population. The causes of excess mortality in these patients seem to various, 
but dyskalemia is a common cause among the patients with ESRD undergoing 
hemodialysis.
Key Words: Potassium; Balance; Hemodialysis
Department of Internal Medicine, Gangnam 
Severance Hospital, Yonsei University College 
of Medicine, Seoul, Korea
Received: Feb 14, 2013
Accepted: Feb 18, 2013
Corresponding Author: Sung Kyu Ha, M.D., Ph.D.
Department of Internal Medicine, Gangnam Severance 
Hospital Yonsei University College of Medicine, 146-92, 
Dogok-Dong, Gangnam-Gu, Seoul 135-720, Korea
Tel: +82-2-2019-3313, Fax: +82-2-3463-3882
E-mail: hask1951@yuhs.ac
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
The kidney plays a key role in maintaining potassium 
([K]) homeostasis by excreting excess potassium. Potassium 
excretion primarily depends on renal (about 90%), and 
to a lesser extent (about 10%) on colonic excretion1). How- 
ever, non-renal excretion of [K] and dialytic [K] removal 
are important in regulating potassium balance in ESRD 
patients on hemodialysis because of markedly decreased 
renal excretion of potassium. Total body potassium is app- 
roximately 50 mmol/kg body weight and 2% of total 
body potassium is in the extracellular fluid (ECF) com-
partment and 98% of it in the intracellular fluid (ICF) 
compartment2). Oral [K] intake is initially absorbed in the 
intestine and enters portal circulation. And then, increased 
ECF[K] stimulates insulin release and in turn, insulin facili- 
tates [K] entry into intracellular compartment by stim-
ulating cell membraneNa+-K+ ATPase3). If it is not for 
the rapid shift of [K] from the ECF to ICF compartments, 
serum [K] increased acutely. Excretion of an oral [K] load 
in the kidney and colon is a relatively slow process, re-
quiring 6-12 hours to be completed. So without rapid 
transcelluar shift of serum [K] in the human body, we are 
exposed to hyperkalemic milieu for a while1).
In cases of ESRD patient on maintenance hemodialysis, 
hyperkalemia seems to be primarily related to poor diet-
ary compliance such as too much [K] intake, inadequate 
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dialysis due to noncompliance or vascular access prob-
lems, medications such as ACEIs, [K] sparing diuretics, 
non-selective beta blockers, NSAIDs, and unfractionate 
heparin use4). The prevalence of hyperkalemia in any giv-
en month of HD patients was reported to be about 8.7-10% 
depending on individual centers5). Mortality related to 
the hyperkalemia has been shown to be about 3.1/1,000 
patient-years and mainly related to cardiac rhythm distur- 
bances. So, it is frequently called “a silent and a potential 
life threatening killer” among patients with ESRD under 
maintenance hemodialysis6). In contrast to hyperkalemia, 
much less attention has been paid to the hypokalemia 
in hemodialysis patients because of the low prevalences 
under maintenance hemodialysis patients. Hypokalemia 
increases some risks of ventricular arrhythmias in patients 
with underlying cardiac diseases and a higher incidence 
of ventricular arrhythmias was reported to increase from 
9 to 40% during HD in some studies7). Recently, the num-
bers of the new patient undergoing maintenance hemo-
dialysis are tremendously increasing worldwide. The cause 
of excess mortality in these patients seems to bevarious, 
but dyskalemia is a common cause among the patients 
with ESRD undergoing hemodialysis. In this article, we 
are going to review [K] homeostasis in ESRD and how 
dyskalemia influences morbidity and mortality in main-
tenance hemodialysis patients.
Potassium Homeostasis in the Body
Potassium plays various roles in the body maintenance 
of the resting membrane potential and neuromuscular 
functioning, intracellular acid-base balances, water bala- 
nces, maintenance of cell volume, cell growth, DNA and 
protein synthesis, and enzymatic functions8). Daily [K] intake 
is estimated to range between 50-100mmol, of which 90% 
of [K] intake is excreted by the kidney and the remainder 
by the colon. Complete excretion of ingested [K] can be 
excreted by the kidney in a 6-12 hour period1). Therefore 
short-term maintenance of ECF [K] concentration de-
pends on extra-renal mechanisms that can respond within 
a minutes. The majority of total body [K] is located in the 
intracellular compartment. Many factors influence the dis-
tribution of [K] in the body. The factors stimulating [K] 
shifts from the ECF to ICF compartments include insulin 
release, cathecolamines, metabolic alkalosis, and anabolic 
state. Reverse processes happen in mineral acidosis, hype- 
rosmolarity, non-selective beta-blockade use, and alpha-1 
stimulation. Potassium is freely filtered at the glomerulus 
and approximately 65% of filtered load is reabsorbed in 
the proximal tubule. The collecting duct is the main site 
of the [K] secretion into the urine8). Factors affecting renal 
potassium excretion include; distal nephron sodium de-
livery, the renin-angiotensin-aldosterone system activation, 
vasopressin status, dietary potassium intake, acid-base sta-
tus, distal nephron urine flow, and serum potassium concen- 
tration. Potassium secretion into the lumen of the distal 
nephron is passive and this passive movementof potas-
sium is dependent on the concentration gradient across 
the luminal membrane, the lumen negative electrical gra-
dient (primarily generated by sodium reabsorption) favor-
ing secretion, and the luminal membrane’s permeability 
to potassium9).
Aldosterone plays a key role in the regulation of potassium 
homeostasis. Aldosterone binds to the nuclear mineralocor- 
ticoid receptor within the distal tubule and the principal 
cells in the cortical collecting duct. At a cellular level, aldos-
terone opens apical [Na] channels and enhances Na+-K+ 
ATPase activity on the baso-lateral membranes, resulting 
in an increase in [K] secretion10). The major stimuli for aldo- 
sterone secretion are angiotensinII and elevations in se-
rum [K] level11). Aldosterone also influences extra-renal 
regulation of [K] secretion via increases in colonic and sali-
vary secretion of [K]12).
Hyperkalemia on Maintenance Hemodialysis
Hyperkalemia is defined as a serum [K] concentration- 
greater than 5.0 mEq/L. The kidneys are primarily respon- 
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sible for [K] excretion in healthy adults, it is not surpris-
ing that patients with ESRD are at a high risk population 
for developing hyperkalemia. At any given level of kidney 
function, hyperkalemia is more likely to occur in patients 
who have concurrent medical conditions such as insulin 
deficiency or concurrent use of drugs to interfere with [K] 
secretions such as aldosterone antagonists, angiotensin II 
converting enzyme inhibitors, and/or angiotensin II recep- 
tor antagonists9). Patients with chronic renal failure on 
maintenance hemodialysis develop variety of adaptations 
to compensate for the decrease of renal [K] excretion. In 
this population, extra-renal colonic [K] excretion is a par-
amount importance in defending against hyperkalemia. 
This colonic [K] adaptation is mediated by increased co-
lonic secretion, which is 2-3 fold higher in patients on hemo- 
dialysis than in patients with normal renal function13,14). 
The process of [K] adaptation is facilitated by the increase 
in aldosterone secretion associated with increases in serum 
[K] concentration. The other system defends against hy-
perkalemia by regulating distribution of potassium be-
tween the intracellular and extracellular compartments. 
Many factors influence [K] distribution between the ICF 
and ECF compartments. Insulin and cathecolamines are 
major factors to regulate Na+-K+-ATPase activities over 
the short term period15). Insulin have a major role in po-
tassium adaptationin end-stage renal disease (ESRD), en-
hancing cellular [K] uptake16,17). Prolonged fasting has been 
associated with hyperkalemiain dialysis patients17). Although 
bicarbonatealone has little or no effect on cellular [K] up-
take inpatients with ESRD18), it appears to facilitate in-
sulin’seffect perhaps by correction of acidemia19). Clinical 
data regarding the role ofaldosterone in [K] handling in 
dialysis patients is equivocal20). However, with recent cont- 
rolled trial fails toshow a convincing [K]-lowering effect 
of fludrocortisones21). Secondary hyperparathyroidism is 
a common feature of ESRD patients. It appears to de-
crease cellular uptake of [K] via an increase of intracellular 
calcium, which suppress oxidative metabolism and ATP 
generation of cell and reduce Na+-K+-ATPase activity22). 
Extracellular hypertonicity, usually seen with diabetic hy-
perglycemia23) or hypertonic fluid administration24), caus-
es hyperkalemia on the basisof convective [K] efflux from 
cells and insulin deficiency. Lastly, severe exercise25) and 
hemolysis in the course of hemodialysis26) release large 
amount of [K] into the ECF compartment and may cause 
severe hyperkalemia.
True hyperkalemias on maintenance hemodialysis occur 
by increased dietary [K] intake in interdialytic interval, 
absence of residual renal function which is the main 
sources of [K] removal in the normal persons, reduction 
in dialysis [K] clearance, hypoaldosteronism, metabolic 
acidosis usually seen in ESRD, hypercatabolic state, blood 
transfusions, abnormal colonic [K] secretion, and various 
drugs used in hemodialysis patients (e.g. cox 1&2 inhibitors, 
beta blockers, ACE inhibitors, Angiotensin Receptor blo- 
ckers, postassium sparing diuretics, succinylcholine, digo- 
xin, cyclosporine, tacrolimus, ketoconazol, potassium con- 
taining drugs)3,9,20,24,27). Chronic renal failure is the most 
common cause of [K] retention, especially when GFR falls 
toward 20% of normal. In most patients with nonoliguric 
chronic renal failure, mild hyperkalemia is usual28). In 
cases of chronic renal failure due to diabetes mellitus and 
tubulointerstitial diseases, hyperkalemia is more pronoun- 
ced because of low circulating renin and aldosterone 
levels29). Many drugs used in the intensive care unit (ICU) 
can produce hyperkalemia by decreasing [K] excretion30). 
Shift of the intracellular [K] to extracellular compartment 
may lead to severe hyperkalemia in critically ill patients. 
The traditional concept wasthat metabolic acidosishas 
been implicated as a causative factor of hyperkalemia31). 
This paradigm has been disproved, and changes in serum 
[K] in relation to acid-base disorders are more complex 
than initially thought. The most common forms of acute 
metabolic acidosis in critically ill patients, diabetic ketoa- 
cidosis and lactic acidosis, are not associated with shift 
[K] out of cells32). Hyperkalemia seen with diabetic ketoa- 
cidosis is most likely caused by increased release of int- 
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Table 1. Acute management of hyperkalemia
Treatment Mechanism Dosage/Comment Onset Duration
Calcium Cardiaccell stabilizer 10 mL of 10% solution (calcium gluconate or 
calcium chloride)
Immediate 30-60 mins
Insulin (Regular) ShiftsK into cells 10 U Regular Insulin + Glucose (50 g) IV 15-30 mins 2-4 hrs
Albuterol ShiftsK into cells 10-20 mg by inhaler over 10 min 20-30 mins 2-3 hrs
Sodium bicarbonate ShiftsK into cells In cases of acidosis Hours Duration of infusion
Potassium binding 
resin with sorbitol
Removes K from body Oral: 15-30 g
Retention enema: 30-50 g
4-6 hrs
1 hr
—
—
Hemodialysis Removes K from body Preferred over peritoneal dialysis in acute cases Immediate —
racellular [K] due to the breakdown of muscle cells. 
Hypertonicity of the extracellular fluid causes water to 
exit cells, and [K] is swept out along with water. Unless 
renal function is not adequate to eliminate the excess [K], 
hyperkalemia occurs. This clinical setting may occur in 
patients with uncontrolled diabetes and renal insufficiency 
and can lead to severe hyperkalemia33). Massive tissue break- 
down such as trauma, burn, and rhabdomyolysis, can lead 
to release of [K] into the extracellular space. If renal func- 
tions are severely impaired, hyperkalemia may develop. 
Drugs that impair [K] entry into cells can affect the trans- 
membrane balance of [K]. β-Adrenergic blockers inhibit 
the entry of [K] into cells and, in cases with renal failure, 
can accelerate development of hyperkalemia34). Succinyl- 
choline blocks normal reentry of [K] into cells after depo- 
larization and causes a temporary increase in serum [K]35). 
Digoxin, an inhibitor of cell membrane Na+-K+-ATPase, 
impairs [K] entry into cells, but does not cause significant 
hyperkalemia at usual therapeutic dose36). However, it 
sometimes may cause hyperkalemia with toxic doses37).
Clinical symptoms related to hyperkalemia are nonspe- 
cific and most often, asymptomatic. However, it affects 
cardiac and neuromuscular cells which are particularly 
sensitive to changes in serum [K]. In patients with mild 
to moderate hyperkalemia, patients usually complain of 
muscle weakness, fatigue, paresthesias, palpitations, and 
cardiac arrythmias. As evidenced by characteristic changes 
in the electrocardiogram (ECG) that serve as indicators 
of potential life-threatening arrhythmias, the first sign of 
increased serum [K] is tenting of the T wave. ECG changes 
may progress rapidly in conjunction with serum [K] levels. 
ECG changes include widening of the QRS complex, pro-
gressive development of atrioventricular conduction blocks, 
slow idioventricular rhythm, an ECG tracing that looks 
like a sine wave, ventricular fibrillation, and finally asys-
tole38).  ECG findings are not always sensitive to changes 
in serum [K] levels and there is no absolute level of serum 
[K] associated with a particular ECG abnormality. Some- 
times, normal ECG findings have been described with 
severe hyperkalemia, and in some cases the first manifes-
tation of cardiac changes from hyperkalemia may be ven-
tricular fibrillation39,40). Hyperkalemia can cause neuro-
muscular symptoms such as paresthesias and weakness 
in the arms and legs, followed by a symmetrical flaccid 
paralysis of the extremities that ascends toward the trunk, 
finally involving the respiratory muscles. The cranial nerves 
are usually not affected by hyperkalemia1).
Regardless of the cause, the primary goal of treating 
hyperkalemia in HD patients is to prevent adverse cardiac 
arrythmias. Therapy to lower serum [K] should be started 
immediately when serum [K] level is greater than 6.5mEq/L 
or if the ECG changes show sings of conduction abnor- 
malities. Treatment modalities are aimed at one of three 
mechanisms to prevent or decrease these complications: 
(1) direct antagonism of hyperkalemic effect on the cell 
membrane polarization, (2) movement of extracellular [K] 
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into the intracellular compartment, and (3) removal of [K] 
from the body. Table 1 summarizes acute management 
of hyperkalemia41). However, in patients with hemodial-
ysis, residual renal function is not sufficient to promote 
kaliuresis.If hyperkalemia is not urgent, sodium polystyrene 
sulfonate (Kayexalate) and calcium polystyrene sulfonate 
(Kalimate) can be used. At equilibrium, each gram of resin 
removes about 0.5 to 1mEq of [K]. The usual dose of [K]- 
binding resins are 15 to 30g orally. When given by mouth, 
[K]-binding resin has little effect for 4-6 hours because 
it must transit to the colon to be effective. When given as 
a retention enemas consisting of 30 to 50 g of the resin 
in 70% sorbitol solution, it works within 1 hour. It is 
important, however, that the enema should be retained 
for at least 30 to 60 minutes to obtain the desired ther-
apeutic effect. Unfortunately, the combined use of sorbi-
tol and Kayexalate can cause bowel necrosis and perfora- 
tion. These complications seem to be more likely in seve- 
rely immunocompromised patients or shortly after sur-
gery42). In acute cases when serum [K] needs to be corre- 
cted rapidly, hemodialysis is a preferred mode of therapy. 
Hemodialysis can quickly remove 70 to 150mEq of [K] and 
should be used asa gold standardtreatment modality when 
other treatments fail43). In addition to the implementation 
of rapid treatment, the causes of hyperkalemia should 
be sought and immediatedlycorrected, and offending drugs 
should be discontinued when possible. In cases of chronic 
hyperkalemia, dietary restriction of [K] is the mainstay of 
management in these patients (40-70 mEq/day). If acido-
sis is present, sodium bicarbonate is helpful by increasing 
distal nephron sodium delivery, inducing kaliuresis, and 
promoting intracellular potassium shift. An additional alter- 
native is the use of [K]-binding resins such as Kayexalate 
or Kalimate combined with sorbitol to avoid constipation, 
at smaller doses given daily or every other day.
Hypokalemia on Maintenance Hemodialysis
Hypokalemia is usually defined as serum [K] less than 
3.5 mEq/L. Hypokalemia usually occurs as a consequence 
of [K] depletion due to either increased excretion or in-
adequate intake. However, shift of [K] in the extracellular 
to intracellular compartmentsalso can cause hypokalemia. 
In cases of ESRD patients on hemodialysis, hypokalemia 
is a relatively rare event comparing to hyperkalemia. The 
precise prevalence of hypokalemia in maintenance HD 
patients is unknown but the prevalence is various among 
different centers5,44,45). Most hypokalemic patients are 
asymptomatic depending on serum [K] levels but it can 
be associated with mild muscle weakness to serious sud-
den cardiac death. The consequences of hypokalemia result 
to alterations in the resting membrane potential of cardiac 
and neuromuscular cells. The most serious and potentially 
fatal effects of hypokalemia are related to disturbances 
in cardiac rhythm that can lead to cardiac arrest. Howe- 
ver, cardiac arrest caused by hypokalemia occurs almost 
exclusively in patients with underlying cardiac disease or 
patients taking digitalis. Characteristic electrocardiogra- 
phic (ECG) changes associated with hypokalemia include 
broad, flat T waves, ST depression, the appearance of 
U waves, QT interval prolongation, and finally ventricular 
arrhythmias leading to cardiac arrest46). When serum [K] 
is less than 3.0 mEq/L, generalized weakness can develop 
and serum [K] decreases to less than 2.5 mEq/L, muscle 
necrosis and rhabdomyolysis can occur. With progression 
of hypokalemia, an ascending muscle paralysis develops, 
leading to respiratory failure and arrest5,8). Hypokalemia 
in maintenance hemodialysis patients is less frequent con-
dition compared to hyperkalemia (0.3-0.5% Vs. 8.7-10%)5) 
and can be caused by low dietary potassium intake, mal-
nutrition, chronic diarrhea, prescription of drugs that can 
increase colonic [K] excretions such as mineralocorticoids 
and imprudent use of [K]-exchange resins8,45). One recent 
study conducted on Non Dialysis Dependent (NDD)-CKD 
population, overall mortality was significantly associated 
with both higher and lower serum potassium levels even 
after adjustments for relevant confounders. They also 
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Table 2. Treatment of hypokalemia
IV KCl : Maximum rate, 20 mEq/hr with cardiac monitoring 
        Reassess serum [K] concentration after 60mEq infusion
        IV administration should be used cautiously in cases of;
　　　　　　Cardiac arrhythmia with rapid ventricular response
　　　　　　Cardiac arrhythmia due to digoxin toxicity
　　　　　　Severe diarrhea
　　　　　　Severe myopathy with muscle necrosis
　　　　　　Paralysis
Oral KCl: 20-80 mEq/day in divided doses
         All other settings except renal tubular acidosis
         In cases of renal tubular acidosis, Oral KHCO3 or K-
         Citratewill be used.
found that hypokalemias were significantly associated 
with faster loss of kidney function over time, even after 
adjusting for other known risk factors such as BP, protei-
nuria and comorbid conditions. They concluded that hypo- 
and hyper-kalemia are associated with higher mortality 
in NDD-CKD patients47).
The goal of treatment in hypokalemia on maintenance 
hemodialysis is to prevent cardiac rhythm disturbances 
and serious neuromuscular weaknesses. Supplementation 
of [K] is the main treatment for hypokalemia and is usu-
ally achieved with the oral administration of potassium 
preparations. There are four types of potassium prepara-
tions: potassium chloride, potassium phosphate, potas-
sium bicarbonate and potassium citrate. Potassium phos-
phate is used to treat hypokalemia with hypophospha- 
temia. Potassium bicarbonate or citrate is preferred in 
patients with hypokalemia and metabolic acidosis. In all 
other settings, potassium chloride should be used. Con- 
ditions requiring emergent therapy are usually rare. In 
general, plasma [K] decreases by approximately 0.3 mEq/L 
for each 100 mEq decrease in total body [K]. Potassium 
replacement should be given orally except when severe 
hypokalemia is associated with respiratory or cardiac insta- 
bility, in which case the IV route is prefered. When given 
intravenously, the rate of [K] administration should not 
exceed 20mmol/hourto minimize possible iatrogenic hyper- 
kalemia. For IV infusion of [K], an infusion pump and 
continuous cardiac monitoring are mandatory. When pota- 
ssium is administered intravenously through a peripheral 
vein, the concentrations should not exceed 50 mmol/l. 
IV fluids containing higher [K] concentration are often 
painful and cause peripheral vein irritation. Serum [K] 
level should be followed closely, especially when using 
IV route or higher doses, to prevent the development of 
hyperkalemia because ESRD patients with MHD have no 
residual renal function to excrete excess potassium48). 
Table 2 shows summaries of the treatment of hypokalemia3).
Conclusion
Dyskalemia is a frequent electrolyte imbalance ob-
served among the maintenance hemodialysis patients. In 
case of hyperkalemia, it is frequently “a silent and a poten- 
tial life threatening electrolyte imbalance” among patients 
with ESRD under maintenance hemodialysis. The preva-
lence of hyperkalemia in HD patients was reported to 
be about 8.7-10%. Mortality related to hyperkalemia has 
been shown to be about 2-5% of deaths among patients 
with ESRD5) and about 24% of patients with HD requi- 
red emergency hemodialysis due to severe hyperkale- 
mia1). In contrast to the hyperkalemia, hypokalemia in 
maintenance hemodialysis patients is less frequent condi- 
tion. The precise prevalence of hypokalemia in maintenance 
HD patients is unknown but the prevalence is various 
among different centers5,44,45). Most hypokalemic patients 
are asymptomatic depending on serum [K] levels but it 
can be associated with mild muscle weakness to serious 
sudden cardiac death. It can be caused by low dietary 
potassium intake, malnutrition, chronic diarrhea, pres- 
cription of drugs that can increase colonic [K] excretions 
such as mineralocorticoids and [K]-exchange resins8,45). 
Much less attention has been paid to the hypokalemia 
in hemodialysis patients because of the low prevalence un-
der maintenance hemodialysis patients. However, in cases 
of severe hypokalemia, we also pay attention to prevent 
cardiac rhythm disturbances and serious neuromuscular 
weaknesses.
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